II 

118TH CONGRESS 

2D SESSION S. 5510 

To amend title XI of the Social Security Act to require pharmaceutical 

and device manufacturers to publicly disclose covered payments made 

to patient advocacy organizations. 

IN THE SENATE OF THE UNITED STATES 

DECEMBER 12, 2024 

Mr. GRASSLEY (for himself and Ms. HASSAN) introduced the following bill; 

which was read twice and referred to the Committee on Finance 

A BILL 

To amend title XI of the Social Security Act to require 

pharmaceutical and device manufacturers to publicly disclose covered payments made to patient advocacy organizations. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Open Payments Ex5 pansion Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•S 5510 IS

1 SEC. 2. DISCLOSURE OF PHARMACEUTICAL AND DEVICE 

2 MANUFACTURER COVERED PAYMENTS TO 

3 PATIENT ADVOCACY ORGANIZATIONS. 

4 (a) IN GENERAL.—Section 1128G of the Social Secu5 rity Act (42 U.S.C.1320a–7h) is amended— 

6 (1) in subsection (a), by adding at the end the 

7 following new paragraph: 

8 ‘‘(3) DONATIONS TO PATIENT ADVOCACY ORGA9 NIZATIONS.— 

10 ‘‘(A) IN GENERAL.—In addition to the re11 quirements under paragraphs (1) and (2), on 

12 March 31, 2026, and on the 90th day of each 

13 calendar year beginning thereafter, any applica14 ble manufacturer or applicable group pur15 chasing organization shall submit to the Sec16 retary, in such electronic form as the Secretary 

17 shall require, details regarding any covered pay18 ment made by such manufacturer or organiza19 tion to any patient advocacy organization, in20 cluding— 

21 ‘‘(i) the name of the patient advocacy 

22 organization; and 

23 ‘‘(ii) the amount of the covered pay24 ment. 

25 ‘‘(B) DEFINITIONS.—In this paragraph: 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•S 5510 IS

1 ‘‘(i) COVERED PAYMENT.—The term 

2 ‘covered payment’ means any— 

3 ‘‘(I) payment or other transfer of 

4 value; or 

5 ‘‘(II) indirect payment or other 

6 transfer of value. 

7 ‘‘(ii) INDIRECT PAYMENT OR OTHER

8 TRANSFER OF VALUE.—The term ‘indirect 

9 payment or other transfer of value’ means 

10 a payment or other transfer of value made 

11 by an applicable manufacturer or applica12 ble group purchasing organization to a pa13 tient advocacy organization through a third 

14 party, where the applicable manufacturer 

15 or applicable group purchasing organiza16 tion requires, instructs, directs, or other17 wise causes the third party to provide the 

18 payment or transfer of value, in whole or 

19 in part, to a patient advocacy organization. 

20 ‘‘(iii) PATIENT ADVOCACY ORGANIZA21 TION.—The term ‘patient advocacy organi22 zation’ means an organization described in 

23 section 501(c)(3) of the Internal Revenue 

24 Code of 1986 that is exempt from taxation 

25 under section 501(a) of such Code that— 


ssavage on LAPJG3WLY3PROD with BILLS
4 

•S 5510 IS

1 ‘‘(I) provides education, advo2 cacy, and support services oriented to3 wards patients and caregivers; 

4 ‘‘(II) is concerned with a medical 

5 condition diagnosed by a licensed 

6 medical practitioner who is in good 

7 standing with a State licensing body; 

8 or 

9 ‘‘(III) has a mission that seeks to 

10 help vulnerable individuals affected by 

11 medical conditions or to help the fami12 lies of such vulnerable individuals and 

13 takes actions consistent with such 

14 mission.’’; and 

15 (2) in subsection (c)(1)(C)(ix), by striking ‘‘or 

16 covered recipient’’ each place it appears and insert17 ing ‘‘covered recipient, or patient advocacy organiza18 tion’’. 

19 (b) ADMINISTRATION.—Chapter 35 of title 44, 

20 United States Code, shall not apply to this section or the 

21 amendments made by this section. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS